Close Menu

The company launched a "core" service using Illumina microarray genotyping, and has plans for an expanded NGS offering with Quest Diagnostics.

The developers anticipate that their new approach may enable noninvasive and continuous monitoring of glucose, lactate, and other clinical parameters.

The method uses DESI-MS imaging to analyze fine-needle aspiration biopsies and could help evaluate cases where traditional cytology is inconclusive.

The company has collected initial evidence for an algorithmic method to predict immunotherapy response, and is studying its technology in treatment monitoring.